



RECEIVED

OCT 1 5 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#17/0

IN RE APPLICATION OF:

MINAKO HIJIKATA ET AL.

: GROUP ART UNIT: 1634

SERIAL NO.: 09/813,990

FILED: MARCH 22, 2001

: EXAMINER: CHAKRABARTI, A.

FOR: GENETIC POLYMORPHISM OF

MXA PROTEIN AND USE

THEREOF

AMENDMENT AND REQUEST FOR RECONSIDERATION

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Responsive to the Official Action dated July 11, 2002, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks.

IN THE CLAIMS

Please cancel Claims 1-17.

Please and the following claims.

18. A polynucleotide suitable for predicting the efficacy of interferon therapy using interferon- α and/or interferon- β for treating an individual who suffers from hepatitis C virus, comprising a polynucleotide selected from the group consisting of:

- (at) the polynucleotide of Sequence ID No. 1 in the sequence listing;
- (bt) a modified polynucleotide derived from (at) by inclusion of one or several

10/10/2002 HVUDNG1 00000110 09813990

01 FC:103

198.00 OP